Medicare Enrolled
Dr. Nirav Pavasia, M.D.
Neurology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Pavasia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pavasia? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pavasia
Dr. Nirav Pavasia is a neurology in Dallas, TX, with 15 years in practice. Based on federal Medicare data, Dr. Pavasia performed 14,455 Medicare services across 1,576 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pavasia received a total of $1,150,800 from 88 pharmaceutical and/or device companies across 2548 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pavasia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice▲ Top 6% volume in TX$ $1,150,800 industry payments
Medicare Practice Summary
Medicare Utilization ↗14,455
Medicare services
Top 6% in TX for neurology
1,576
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~964 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, abobotulinumtoxina, 5 units | 4,764 | $7 | $9 |
| Botox injection (Xeomin), per unit | 3,810 | $4 | $7 |
| Injection, rimabotulinumtoxinb, 100 units | 1,480 | $9 | $12 |
| Office visit, established patient, complex (40-54 min) | 580 | $136 | $275 |
| MRI contrast dye injection (gadoterate) | 553 | $0 | $12 |
| Neuromuscular re-education therapy, per 15 min | 420 | $22 | $143 |
| Physical therapy exercise, per 15 min | 324 | $18 | $142 |
| Functional activity therapy | 272 | $25 | $124 |
| Office visit, established patient (30-39 min) | 248 | $90 | $215 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 235 | $35 | $213 |
| Chronic care management, first 20 min/month | 219 | $44 | $225 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 144 | $40 | $445 |
| Remote patient monitoring management, 20 min/month | 125 | $35 | $50 |
| Remote patient monitoring device, 30 days | 120 | $34 | $60 |
| Punch biopsy, each additional skin growth | 95 | $47 | $85 |
| Self-care/home management training, per 15 min | 92 | $21 | $122 |
| Chronic care management, additional 20 min/month | 86 | $33 | $75 |
| Group therapy session | 82 | $11 | $50 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 78 | $24 | $350 |
| New patient office visit, complex (60-74 min) | 71 | $156 | $535 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 64 | $151 | $517 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 60 | $62 | $203 |
| Punch biopsy, first skin growth | 55 | $99 | $190 |
| Evaluation of neuropsychological test, first hour | 53 | $104 | $325 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 53 | $28 | $225 |
| Administration of psychological or neuropsychological test by technician, each additional 30 minutes | 53 | $28 | $225 |
| Hospital follow-up visit, high complexity | 51 | $95 | $256 |
| Walking/gait training therapy, per 15 min | 40 | $18 | $150 |
| Mri scan of brain before and after contrast | 33 | $175 | $1,651 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 28 | $31 | $75 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 27 | $11 | $75 |
| Initial hospital admission, high complexity | 26 | $138 | $300 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 25 | $91 | $522 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 25 | $14 | $115 |
| Office visit, established patient (20-29 min) | 25 | $60 | $175 |
| Evaluation of neuropsychological test, each additional hour | 21 | $79 | $325 |
| Evaluation for physical therapy, typically 30 minutes | 18 | $81 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$1,150,800
Total received (2018-2024)
Avg $164,400/year across 7 years
Top 0% in TX for neurology
88
Companies
2,548
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,053,165 (91.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$83,555 (7.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,080 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$186,007
2023$201,460
2022$200,137
2021$160,534
2020$70,073
2019$203,807
2018$128,783
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
MDD US Operations, LLC
$193,170
Neurocrine Biosciences, Inc.
$177,904
Kyowa Kirin, Inc.
$156,011
ACADIA Pharmaceuticals Inc
$123,536
Adamas Pharmaceuticals, Inc.
$115,974
US WorldMeds, LLC
$74,304
ABBVIE INC.
$72,768
Amneal Pharmaceuticals LLC
$50,382
Neurocrine BioSciences, Inc.
$48,245
Acorda Therapeutics, Inc
$36,232
Boston Scientific Corporation
$24,657
Sunovion Pharmaceuticals Inc.
$18,546
Teva Pharmaceuticals USA, Inc.
$12,692
Lundbeck LLC
$12,663
Abbott Laboratories
$10,737
AbbVie, Inc.
$5,293
AbbVie Inc.
$4,629
UCB, Inc.
$4,481
Eli Lilly and Company
$1,315
Merz Pharmaceuticals, LLC
$515
Greenwich Biosciences, Inc.
$473
GE HEALTHCARE
$406
Ipsen Biopharmaceuticals, Inc
$403
PFIZER INC.
$398
Novartis Pharmaceuticals Corporation
$264
Alexion Pharmaceuticals, Inc.
$262
Grifols USA, LLC
$193
CSL Behring
$187
Avion Pharmaceuticals
$180
Akcea Therapeutics, Inc.
$173
Lilly USA, LLC
$172
Medtronic USA, Inc.
$168
ARGENX US, INC.
$166
Avanir Pharmaceuticals, Inc.
$166
Eisai Inc.
$165
Genentech USA, Inc.
$164
Allergan Inc.
$157
Supernus Pharmaceuticals, Inc.
$150
EISAI INC.
$148
SK Life Science, Inc.
$146
Alnylam Pharmaceuticals Inc.
$133
Averitas Pharma Inc.
$122
Sumitomo Pharma America, Inc.
$119
Biohaven Pharmaceutical Holding Company Ltd.
$114
Octapharma USA, Inc.
$113
BOSTON SCIENTIFIC CORPORATION
$106
Medtronic, Inc.
$98
Vertical Pharmaceuticals, LLC
$96
Amgen Inc.
$92
Allergan, Inc.
$80
Merz North America, Inc.
$78
Biohaven Pharmaceuticals, Inc.
$77
ARBOR PHARMACEUTICALS, INC.
$69
Celgene Corporation
$65
Biogen, Inc.
$62
Upsher-Smith Laboratories LLC
$56
Impax Laboratories, Inc.
$56
HOSPIRA, INC.
$48
MERZ NORTH AMERICA, INC.
$47
Azurity Pharmaceuticals, Inc.
$37
Marinus Pharmaceuticals, Inc.
$33
Saol Therapeutics Inc.
$32
Takeda Pharmaceuticals U.S.A., Inc.
$31
SCILEX PHARMACEUTICALS INC.
$29
Currax Pharmaceuticals LLC
$29
Neurelis, Inc.
$25
Arbor Pharmaceuticals, Inc.
$25
REVANCE THERAPEUTICS, INC.
$24
Assertio Therapeutics, Inc.
$24
Life Molecular Imaging Ltd
$20
Merck Sharp & Dohme LLC
$19
GENZYME CORPORATION
$19
Exeltis, USA Inc.
$18
TG Therapeutics, Inc.
$18
Cala Health, Inc.
$17
GE Healthcare
$16
Otsuka America Pharmaceutical, Inc.
$16
Janssen Pharmaceuticals, Inc
$15
Harmony Biosciences LLC
$15
Horizon Therapeutics plc
$15
MITSUBISHI TANABE PHARMA AMERICA, INC.
$15
Mitsubishi Tanabe Pharma America, Inc.
$14
NS Pharma, Inc.
$13
Jazz Pharmaceuticals Inc.
$13
Ultragenyx Pharmaceutical Inc.
$12
Xeris Pharmaceuticals, Inc.
$12
AQUESTIVE THERAPEUTICS, INC.
$12
Cycle Pharmaceuticals Inc
$9
Top 3 companies account for 45.8% of total payments
Associated products mentioned in payments ›
ACTIVA · ACTIVA PC · AFINITOR · AIMOVIG · AJOVY · AMPLATZER Occluders · AMYVID · APOKYN · APTIOM · AUBAGIO · AUSTEDO · Aimovig · Apokyn · Austedo XR · Axium INS DRG IPG · BOTOX · BOTOX THERAPEUTIC · BRIUMVI · Briviact · CALA TRIO · COMIRNATY · CONFIRM RX · COPAXONE · CREXONT · Cardiovascular- Research only · DAXXIFY · DAYBUE · DBS IPGs · DIVIGEL · DUOPA · DYSPORT · Deep Brain Stimulation · Dhivy · Duopa · Dysport · EMGALITY · EPIDIOLEX · Enspryng · Epidiolex · Fintepla · Fycompa · GAMMAGARD · GENERAL DBS · GENERAL DBS · GILENYA · GOCOVRI · Gamunex-C · General - DBS · Gocovri · Gralise · HORIZANT · Hizentra · Horizant · INBRIJA · INFINITY · INGREZZA · Infinity DBS Pulse Generators · KESIMPTA · KEVEYIS · KYNMOBI · LATUDA · LEADPOINT · LYRICA · Leqembi · MAYZENT · MYOBLOC · NEURACEQ · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Neuromodulation Dspsbls and Accs · Nourianz · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONFI · ONGENTYS · ONGENTYS 50MG CAPSULES 30 · ONPATTRO · ONZETRA XSAIL · OSMOLEX ER · OXTELLAR XR · Ongentys · PANZYGA · PAXLOVID · PERCEPT PC BRAINSENSE · PURIFIED CORTROPHIN GEL · Ponvory · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUTENZA · RADICAVA · RYTARY · Radicava · Rystiggo · SKYCLARYS · SOLIRIS · SYMPAZAN · Soliris · TEGSEDI · TROKENDI XR · Tascenso ODT · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VERCISE · VILTEPSO · VYALEV · VYEPTI · VYVGART · VYVGART HYTRULO · Vercise · Vimpat · Wakix · XADAGO · XEOMIN · Xadago · Xeomin · ZEPOSIA · ZTALMY · ZTLido · Zinbryta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for neurology in TX.
Equivalent to $7,961 per 100 Medicare services performed
Geographic Context
Neurologys within 10 mi
237
Per 100K population
9.1
County median income
$74,149
Nearest hospital
NEXUS CHILDRENS HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Pavasia is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and high industry engagement (speaking/promotional, top 0%), with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Pavasia experienced with injection, abobotulinumtoxina, 5 units?
Based on Medicare claims data, Dr. Pavasia performed 4,764 injection, abobotulinumtoxina, 5 units services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pavasia receive payments from pharmaceutical companies?
Yes. Dr. Pavasia received a total of $1,150,800 from 88 companies across 2,548 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pavasia's costs compare to other neurologys in Dallas?
Dr. Pavasia's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pavasia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologys in Dallas
Browse neurologys in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Neurologys in TX
Neurologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologys in TX
Which TX neurologys receive the most from drug and device companies.
By company
MDD US Operations, LLC Payments to Doctors
See all physicians who received payments from MDD US Operations, LLC.
By company
Neurocrine Biosciences, Inc. Payments to Doctors
See all physicians who received payments from Neurocrine Biosciences, Inc..
By company
Kyowa Kirin, Inc. Payments to Doctors
See all physicians who received payments from Kyowa Kirin, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology